Results of an Open Multicentre Study with 455 Patients with Coronary Heart Disease, Treated with Gallopamil for 1 Year
- 13 Downloads
A 1-year trial was carried out under general practice conditions to study the efficacy and safety of gallopamil. There were 67 trial centres throughout the Federal Republic of Germany with, in all, 455 patients (254 men, 201 women) with coronary heart disease demonstrated by electrocardiography and anginal symptoms. The average age of the patients was 62 years (men) and 66 years (women). After a 14-day placebo period the patients were given, on average, one 50 mg tablet of gallopamil 2 to 3 times a day. 2 weeks before and 8 weeks after the start of treatment nitroglycerin consumption and the frequency of attacks were checked. The chek-ups were done before the start of treatment and at 1 week, 1, 3, 6, 9 and 12 months after treatment started.
Unable to display preview. Download preview PDF.